Financial PerformanceNet loss was $18.8M, or ($0.49) per share, moderately higher than our estimated loss of $15.5M.
Funding RisksThe company may need to raise additional capital within the next 12 months, indicating a potential financial challenge.
Regulatory RisksRisks include failure of product candidates in clinical trials, failure to secure regulatory approval, and potential dilution risk, which could impact the company's future valuation.